1. Home
  2. INBS vs CDIO Comparison

INBS vs CDIO Comparison

Compare INBS & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intelligent Bio Solutions Inc.

INBS

Intelligent Bio Solutions Inc.

HOLD

Current Price

$1.62

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Logo Cardio Diagnostics Holdings Inc.

CDIO

Cardio Diagnostics Holdings Inc.

HOLD

Current Price

$1.69

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INBS
CDIO
Founded
2016
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
6.1M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
INBS
CDIO
Price
$1.62
$1.69
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 34.9K
27.3K
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $1,980,484.00
$14,825.00
Revenue This Year
$44.72
$168,534.06
Revenue Next Year
$44.26
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.54
$0.97
52 Week High
$24.90
$7.91

Technical Indicators

Market Signals
Indicator
INBS
CDIO
Relative Strength Index (RSI) 43.59 43.73
Support Level $1.52 $1.72
Resistance Level $1.92 $2.17
Average True Range (ATR) 0.11 0.13
MACD 0.04 -0.01
Stochastic Oscillator 56.72 34.62

Price Performance

Historical Comparison
INBS
CDIO

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.

About CDIO Cardio Diagnostics Holdings Inc.

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

Share on Social Networks: